In 2016 the national IBD audit is coming to an end, and the IBD Registry is becoming the vehicle for the biological therapies audit and quality improvement programme. Teams can participate using a choice of data entry systems including some local systems they may have in their hospital already.
The IBD Registry provides the infrastructure to capture pseudonymised IBD patient data and link it with routinely collected NHS hospital statistics. Bringing this data together for the first time will:
- Drive continuous improvement in patient care and access to care across the UK
- Inform commissioning and service design
- Improve our understanding of long term outcomes
- Provide local, regional & national data in order to better define the pattern of ulcerative colitis and Crohn’s disease
- Support IBD research
Being part of the IBD Registry will give participating teams access to better local data to manage their biologics patients and IBD service more effectively, while patients, clinicians and the NHS will all benefit from national audit of the safety and appropriate use of biologics and biosimilars. In time, the combined UK data will become a unique resource for real-world clinical effectiveness and health economic studies in IBD care.
The audit and Registry teams are working closely to manage the transition and you can find a list of frequently asked questions here:
FAQs on IBD programme transition to Registry